BioSpace News Archive

BioMarin Pharmaceutical Inc. announced financial results for the six months and second quarter ended June 30, 2023.

Arvinas, Inc. and Pfizer Inc. announced that the U.K. Innovative Licensing and Access Pathway Steering Group, which consists of The AWTTC, The MHRA, the NICE, and the SMC, has awarded an Innovation Passport to vepdegestrant, an investigational PROTAC® ER degrader, for the treatment of patients with estrogen receptor +/ human epidermal growth factor receptor 2- locally-advanced breast cancer or metastatic breast cancer.

Axial3D today announced that it is the first to receive FDA clearance for an automated, AI-driven, cloud-based segmentation platform for orthopedic trauma, orthopedic, maxillofacial, and cardiovascular applications.

Quanterix’s Simoa ® Technology Powers Large, International Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Neurological Disease Activity in Pediatric Patients.

Melinta Therapeutics, LLC today announced the availability of REZZAYO™ (rezafungin for injection), for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade.

Kandu Health, Inc. today announced preliminary outcomes from the first 40 stroke survivors served by its program.

Smirta is pleased to announce that OneOncology has selected Smirta as a preferred vendor to provide Smirta’s OncoSmart® oncology infusion schedule optimization platform to the OneOncology network of physician practices.

Globus Medical, Inc. announced the commercial launch of the MARVEL™ Growing Rod System, which is designed for pediatric patients with early onset scoliosis to obtain and maintain correction while allowing for growth through minimally invasive distraction.

Mustang Bio, Inc. today announced that, on July 28, 2023, it amended its previously announced asset purchase agreement with uBriGene (Boston) Biosciences Inc.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday, August 1, 2023, at 8:30 AM ET to discuss results for the second quarter 2023 and provide a business outlook for remainder of the year.